Study guide

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines

Key Takeaways Explain This Topic AI

Hypertension Canada guidelines recommend standard blood pressure targets < 140/90 mmHg, diabetes targets < 130/80 mmHg, and intensive systolic targets < 120 mmHg (via automated office blood pressure) for high-risk patients.

First-line antihypertensive classes include thiazide/thiazide-like diuretics (chlorthalidone, indapamide preferred), ACE inhibitors, ARBs, and dihydropyridine CCBs; dual combination therapy is indicated upfront if blood pressure is >= 20/10 mmHg above target.

CCS dyslipidemia guidelines establish statin-indicated conditions (clinical CVD, AAA, diabetes age >= 40, CKD age >= 50 with eGFR < 60 or ACR >= 3.0 mg/mmol, LDL-C >= 5.0 mmol/L) with a primary LDL-C target < 2.0 mmol/L or >= 50% reduction.

Guideline-directed medical therapy for HFrEF (LVEF <= 40%) requires the 'Four Pillars': ARNI (sacubitril/valsartan) or ACEi/ARB, evidence-based beta-blockers (bisoprolol, carvedilol, metoprolol succinate), MRAs (spironolactone, eplerenone), and SGLT2 inhibitors.

Atrial fibrillation stroke prevention uses the CHADS-65 algorithm; patients aged >= 65 or with any CHADS risk factor warrant oral anticoagulation, with DOACs preferred over warfarin.

Last updated: August 2026

Hypertension Management and Canadian Guidelines

Hypertension is the single leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease in Canada. Hypertension Canada publishes evidence-based clinical practice guidelines outlining diagnostic thresholds, blood pressure (BP) measurement methodologies, glycemic and renal comorbidities, and pharmacological selection algorithms.

Blood Pressure Measurement and Diagnostic Thresholds

Accurate diagnosis relies on standardized measurement. Automated Office Blood Pressure (AOBP) —the preferred clinic-based method—involves an automated device taking multiple consecutive oscillometric readings while the patient rests alone in a quiet room, substantially reducing the white-coat effect.

  • Measurement Modality Diagnostic Threshold for Hypertension
  • Automated Office Blood Pressure (AOBP) ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg
  • Non-Automated / Manual Office BP ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg
  • Ambulatory BP Monitoring (ABPM) - 24-Hour Average ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg
  • Ambulatory BP Monitoring (ABPM) - Daytime Mean ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg
  • Home BP Monitoring (HBPM) - Average ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg
  • Target Blood Pressure Levels

Hypertension Canada establishes risk-stratified BP targets:

Standard Target: < 140 / 90 mmHg < 140/90\text{ mmHg} < 140/90 mmHg for general hypertensive adults without diabetes or high cardiovascular risk.

Diabetes Mellitus Target: < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg to reduce microvascular (nephropathy, retinopathy) and macrovascular complications.

Intensive / High-Risk Target (SPRINT Criteria): Systolic BP < 120 mmHg < 120\text{ mmHg} < 120 mmHg (measured by AOBP) for individuals aged ≥ 50 \ge 50 ≥ 50 years with high cardiovascular risk (established clinical or subclinical cardiovascular disease, CKD with eGFR 20 − 59 mL/min / 1.73 m 2 20-59\text{ mL/min}/1.73\text{ m}^2 20 − 59 mL/min /1.73 m 2 , Framingham Risk Score ≥ 15 % \ge 15\% ≥ 15% , or age ≥ 75 \ge 75 ≥ 75 years). Intensive control requires close monitoring for hypotension, syncope, acute kidney injury, and electrolyte disturbances.

First-Line Pharmacotherapy and Combination Strategies

For adults without compelling indications, first-line monotherapy includes:

Thiazide / Thiazide-like Diuretics: Chlorthalidone ( 12.5 − 25 mg 12.5-25\text{ mg} 12.5 − 25 mg daily) and Indapamide ( 1.25 − 2.5 mg 1.25-2.5\text{ mg} 1.25 − 2.5 mg daily) are preferred over hydrochlorothiazide (HCTZ) due to longer duration of action and superior cardiovascular outcome data.

Angiotensin-Converting Enzyme (ACE) Inhibitors: (e.g., ramipril, perindopril, enalapril) or Angiotensin Receptor Blockers (ARBs): (e.g., candesartan, valsartan, telmisartan). ARBs are preferred alternatives when ACE inhibitors cause bradykinin-mediated dry cough or angioedema.

Dihydropyridine Calcium Channel Blockers (CCBs): (e.g., amlodipine, felodipine). Effective across all age groups and ethnicities, causing peripheral vasodilation (common adverse effect: dose-dependent peripheral edema).

Important Clinical Pearl: Beta-blockers are not recommended as first-line monotherapy in uncomplicated hypertension for patients aged ≥ 60 \ge 60 ≥ 60 years due to inferior stroke and cardiovascular event reduction compared to other first-line agents.

Dual Combination Therapy: Upfront initiation of two first-line antihypertensives (preferably as a single-pill combination) is recommended when baseline systolic BP is ≥ 20 mmHg \ge 20\text{ mmHg} ≥ 20 mmHg above target or diastolic BP is ≥ 10 mmHg \ge 10\text{ mmHg} ≥ 10 mmHg above target. Synergistic combinations include ACEi/ARB + Dihydropyridine CCB or ACEi/ARB + Thiazide-like diuretic. Dual renin-angiotensin-aldosterone system (RAAS) blockade (ACEi + ARB + direct renin inhibitor) is strictly contraindicated due to increased risks of hyperkalemia, syncope, and acute kidney injury without added clinical benefit.

  • Compelling Indication Preferred First-Line Antihypertensives
  • Recent Myocardial Infarction / CAD Beta-blocker + ACEi or ARB
  • Heart Failure with Reduced Ejection Fraction ARNI (or ACEi/ARB) + Beta-blocker + MRA + SGLT2i
  • Chronic Kidney Disease with Proteinuria ACEi or ARB (titrated to maximum tolerated dose)

Diabetes Mellitus with Microalbuminuria ACEi or ARB (ACR > 2.0 mg/mmol > 2.0\text{ mg/mmol} > 2.0 mg/mmol in males, > 2.8 mg/mmol > 2.8\text{ mg/mmol} > 2.8 mg/mmol in females)

  • Isolated Systolic Hypertension (Elderly) Thiazide-like diuretic or Dihydropyridine CCB or ARB
  • Dyslipidemia and Atherosclerotic Risk Reduction

The Canadian Cardiovascular Society (CCS) dyslipidemia guidelines prioritize comprehensive cardiovascular risk assessment using the modified Framingham Risk Score (FRS) or Cardiovascular Life Expectancy Model (CLEM), stratifying 10-year risk of cardiovascular events into Low ( < 10 % < 10\% < 10% ), Intermediate ( 10 − 19.9 % 10-19.9\% 10 − 19.9% ), and High ( ≥ 20 % \ge 20\% ≥ 20% ).

Statin-Indicated Conditions (Automatic High Risk)

Patients meeting any of the following criteria are designated high risk and warrant immediate statin therapy regardless of baseline FRS:

Clinical Atherosclerotic Cardiovascular Disease (ASCVD): Acute coronary syndrome, stable angina, prior MI, CABG/PCI, stroke, TIA, peripheral arterial disease (PAD).

Abdominal Aortic Aneurysm (AAA): Infrarenal aortic diameter ≥ 3.0 cm \ge 3.0\text{ cm} ≥ 3.0 cm or prior aneurysm repair.

Diabetes Mellitus: Age ≥ 40 \ge 40 ≥ 40 years, or age ≥ 30 \ge 30 ≥ 30 with disease duration ≥ 15 \ge 15 ≥ 15 years, or microvascular disease (retinopathy, nephropathy, neuropathy).

Chronic Kidney Disease (CKD): Age ≥ 50 \ge 50 ≥ 50 years with eGFR < 60 mL/min / 1.73 m 2 < 60\text{ mL/min}/1.73\text{ m}^2 < 60 mL/min /1.73 m 2 or urinary albumin-to-creatinine ratio (ACR) ≥ 3.0 mg/mmol \ge 3.0\text{ mg/mmol} ≥ 3.0 mg/mmol on ≥ 2 \ge 2 ≥ 2 occasions.

Severe Hypercholesterolemia: Baseline LDL-C ≥ 5.0 mmol/L \text{LDL-C} \ge 5.0\text{ mmol/L} LDL-C ≥ 5.0 mmol/L (suggestive of Familial Hypercholesterolemia) or Genetic Dyslipidemias.

Lipid Targets and Pharmacotherapy Escalation

Primary Target: LDL-C < 2.0 mmol/L \text{LDL-C} < 2.0\text{ mmol/L} LDL-C < 2.0 mmol/L or ≥ 50 % \ge 50\% ≥ 50% reduction from baseline.

Secondary Targets: Non-HDL-C < 2.6 mmol/L < 2.6\text{ mmol/L} < 2.6 mmol/L or Apolipoprotein B (ApoB) < 0.8 g/L < 0.8\text{ g/L} < 0.8 g/L . +-------------------------------------------------------------------------+

  • | CCS DYSLIPIDEMIA ESCALATION ALGORITHM |
  • +-------------------------------------------------------------------------+
  • | 1. MAXIMALLY TOLERATED HIGH-INTENSITY STATIN |
  • | (Atorvastatin 40-80 mg daily OR Rosuvastatin 20-40 mg daily) |
  • | | |
  • | v (If LDL-C remains >= 2.0 mmol/L) |
  • | 2. ADD EZETIMIBE 10 mg DAILY (NPC1L1 Inhibitor; IMPROVE-IT Trial) |
  • | | |
  • | v (If High-Risk/Secondary Prevention |
  • | | and LDL-C remains >= 2.0 mmol/L) |
  • | 3. ADD PCSK9 INHIBITOR (Evolocumab 140 mg SC q2w or Alirocumab) |
  • | |
  • | *SPECIAL INDICATION (REDUCE-IT Criteria): |
  • | If established CVD or DM + 2 risk factors, on statin, with fasting |
  • | Triglycerides 1.5 - 5.6 mmol/L -> Add ICOSAPENT ETHYL 2g PO BID |
  • +-------------------------------------------------------------------------+
  • Statin Safety and Statin-Associated Muscle Symptoms (SAMS)

Statin myopathy spans benign myalgia (muscle ache without CK elevation) to severe rhabdomyolysis (muscle breakdown, CK > 10 × ULN \text{CK} > 10 \times \text{ULN} CK > 10 × ULN , myoglobinuria, acute renal failure). When managing SAMS:

Check serum creatine kinase (CK) and thyroid-stimulating hormone (TSH; untreated hypothyroidism predisposes to statin myopathy).

Discontinue statin until symptoms resolve completely (dechallenge).

Rechallenge with a lower dose of the same statin or switch to a hydrophilic statin (rosuvastatin or pravastatin) or alternate-day dosing (e.g., rosuvastatin 5 − 10 mg 5-10\text{ mg} 5 − 10 mg two to three times weekly).

Heart Failure with Reduced Ejection Fraction (HFrEF)

Heart failure with reduced ejection fraction ( LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% ) requires aggressive neurohormonal blockade. Canadian Cardiovascular Society guidelines mandate rapid uptitration of the "Four Pillars" of Guideline-Directed Medical Therapy (GDMT) to reduce cardiovascular mortality and heart failure hospitalizations.

The Four Pillars of GDMT

Angiotensin Receptor-Neprilysin Inhibitor (ARNI):

Sacubitril/valsartan ( Entresto ) is preferred over ACE inhibitors or ARBs for symptomatic HFrEF (NYHA Class II-IV).

Neprilysin Inhibition: Prevents degradation of natriuretic peptides (BNP, ANP, bradykinin), promoting vasodilation, natriuresis, and antifibrotic effects.

Safety Rule: A mandatory 36-hour washout period is required when switching from an ACE inhibitor to an ARNI to prevent life-threatening angioedema caused by dual bradykinin accumulation.

Evidence-Based Beta-Blockers:

Only three beta-blockers demonstrate mortality reduction in HFrEF: Bisoprolol , Carvedilol , and Metoprolol Succinate (sustained-release). Atenolol, metoprolol tartrate, and propranolol do not confer equivalent survival benefits.

Initiate only in stable, euvolemic patients at low starting doses ("start low, go slow") and titrate every 2-4 weeks to target doses.

Mineralocorticoid Receptor Antagonists (MRAs):

Spironolactone ( 12.5 − 50 mg 12.5-50\text{ mg} 12.5 − 50 mg daily) or Eplerenone ( 25 − 50 mg 25-50\text{ mg} 25 − 50 mg daily).

Monitor serum potassium and renal function at 1, 4, 8, and 12 weeks. Withhold or reduce dose if serum potassium > 5.5 mmol/L \text{potassium} > 5.5\text{ mmol/L} potassium > 5.5 mmol/L or eGFR < 30 mL/min / 1.73 m 2 \text{eGFR} < 30\text{ mL/min}/1.73\text{ m}^2 eGFR < 30 mL/min /1.73 m 2 .

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors:

Dapagliflozin ( 10 mg 10\text{ mg} 10 mg daily) or Empagliflozin ( 10 mg 10\text{ mg} 10 mg daily).

Indicated for all symptomatic HFrEF patients regardless of whether the patient has diabetes mellitus (based on DAPA-HF and EMPEROR-Reduced trials).

Mechanism: Promotes osmotic diuresis, reduces preload/afterload, improves myocardial energetics, and preserves renal function.

Adjunctive Heart Failure Therapies

Loop Diuretics (Furosemide): Titrated to maintain euvolemia; provides symptom relief from pulmonary and peripheral congestion without mortality reduction.

Ivabradine: Inhibits the hyperpolarization-activated cyclic nucleotide-gated ( I f I_f I f ​ ) pacemaker channel in the SA node. Indicated in patients with LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% , in normal sinus rhythm with resting heart rate ≥ 70 bpm \ge 70\text{ bpm} ≥ 70 bpm despite maximally tolerated beta-blocker therapy.

HF with Preserved Ejection Fraction (HFpEF, LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% ): SGLT2 inhibitors are the first class to demonstrate significant reductions in cardiovascular death and hospitalizations in HFpEF (EMPEROR-Preserved, DELIVER), alongside MRA therapy and diuretics for fluid management.

  • Ischemic Heart Disease and Acute Coronary Syndromes (ACS)
  • Chronic Coronary Syndromes (Stable Angina)

Symptom Control (Antianginal Therapy): First-line therapy is a Beta-Blocker (titrated to resting HR 55 − 60 bpm 55-60\text{ bpm} 55 − 60 bpm ). Second-line additions include Dihydropyridine CCBs, Long-acting Nitrates (requiring a daily 10-12 hour nitrate-free interval to prevent nitrate tolerance), or Non-dihydropyridine CCBs (diltiazem, verapamil).

Cardioprotective Vasculoprotection: Low-dose Acetylsalicylic Acid (ASA 81 mg 81\text{ mg} 81 mg daily), High-intensity Statin, and ACE Inhibitor/ARB (especially if concurrent hypertension, diabetes, or CKD).

Acute Coronary Syndromes (STEMI and NSTEMI/Unstable Angina)

Emergency Medical Management: ASA 160 − 325 mg 160-325\text{ mg} 160 − 325 mg chewed immediately, Sublingual Nitroglycerin ( 0.4 mg 0.4\text{ mg} 0.4 mg q5min up to 3 doses; contraindicated if phosphodiesterase-5 inhibitors used within 24-48 hours), supplemental oxygen (only if SpO 2 < 90 % \text{SpO}_2 < 90\% SpO 2 ​ < 90% ), and unfractionated heparin or enoxaparin.

Dual Antiplatelet Therapy (DAPT):

ASA ( 81 mg 81\text{ mg} 81 mg daily indefinitely) PLUS a potent P2Y 12 \text{P2Y}_{12} P2Y 12 ​ Receptor Inhibitor for a standard duration of 12 months following percutaneous coronary intervention (PCI).

Ticagrelor ( 90 mg 90\text{ mg} 90 mg PO BID; PLATO trial) or Prasugrel ( 10 mg 10\text{ mg} 10 mg PO daily; TRITON-TIMI 38 trial) are preferred over Clopidogrel ( 75 mg 75\text{ mg} 75 mg daily) due to superior efficacy and faster, more consistent platelet inhibition.

Contraindications: Prasugrel is contraindicated in patients with a history of stroke or TIA (excess intracranial hemorrhage risk). Ticagrelor causes dyspnea and ventricular pauses, and is contraindicated in active bleeding or history of intracranial hemorrhage.

Atrial Fibrillation: Rate vs. Rhythm Control and Anticoagulation

Atrial fibrillation (AF) management encompasses rate/rhythm control and stroke prevention.

Stroke Risk Assessment: The CHADS-65 Algorithm +-------------------------------------------------------------------------+

  • | CCS CHADS-65 DECISION ALGORITHM |
  • +-------------------------------------------------------------------------+
  • | |
  • | Assess CHADS Criteria: |
  • | C = Congestive Heart Failure |
  • | H = Hypertension |
  • | A = Age >= 65 Years |
  • | D = Diabetes Mellitus |
  • | S = Stroke / TIA / Systemic Embolism (Prior) [Scores 2 points] |
  • | |
  • | Decision Rules: |
  • | - Is Age >= 65 OR is any CHADS risk factor present? |
  • | YES -> Oral Anticoagulation Indicated |
  • | NO -> Assess for Coronary/Vascular Disease: |
  • | - If Vascular Disease present -> ASA 81 mg daily |
  • | - If No Vascular Disease -> No Antithrombotic Therapy |
  • +-------------------------------------------------------------------------+
  • Anticoagulant Selection: DOACs vs. Warfarin

Direct Oral Anticoagulants (DOACs) are strongly preferred over warfarin for non-valvular AF due to lower rates of intracranial hemorrhage and all-cause mortality, rapid onset, predictable pharmacokinetics, and lack of routine INR monitoring.

Anticoagulant Mechanism Standard Dosing Dose Adjustment Criteria

Apixaban Factor Xa Inhibitor 5 mg 5\text{ mg} 5 mg PO BID Reduce to 2.5 mg 2.5\text{ mg} 2.5 mg PO BID if ≥ 2 \ge 2 ≥ 2 of: Age ≥ 80 yr \ge 80\text{ yr} ≥ 80 yr , Body Weight ≤ 60 kg \le 60\text{ kg} ≤ 60 kg , Serum Creatinine ≥ 133 μ mol/L \ge 133\text{ }\mu\text{mol/L} ≥ 133 μ mol/L

Rivaroxaban Factor Xa Inhibitor 20 mg 20\text{ mg} 20 mg PO daily (with food) Reduce to 15 mg 15\text{ mg} 15 mg PO daily if CrCl 15 − 49 mL/min \text{CrCl } 15-49\text{ mL/min} CrCl 15 − 49 mL/min

Dabigatran Direct Thrombin (IIa) Inhibitor 150 mg 150\text{ mg} 150 mg PO BID Reduce to 110 mg 110\text{ mg} 110 mg PO BID if Age ≥ 80 yr \ge 80\text{ yr} ≥ 80 yr , or Age ≥ 75 yr \ge 75\text{ yr} ≥ 75 yr with ≥ 1 \ge 1 ≥ 1 bleeding risk factor

Edoxaban Factor Xa Inhibitor 60 mg 60\text{ mg} 60 mg PO daily Reduce to 30 mg 30\text{ mg} 30 mg PO daily if CrCl 15 − 50 mL/min \text{CrCl } 15-50\text{ mL/min} CrCl 15 − 50 mL/min or Weight ≤ 60 kg \le 60\text{ kg} ≤ 60 kg

Warfarin Vitamin K Antagonist (VKORC1) Individualized (Target INR 2.0 − 3.0 2.0-3.0 2.0 − 3.0 ) Mandatory for mechanical prosthetic heart valves and moderate-to-severe rheumatic mitral stenosis

Reversal Agents for Life-Threatening Bleeding

Dabigatran: Idarucizumab ( Praxbind ) — humanized monoclonal antibody fragment ( 5 g 5\text{ g} 5 g IV).

Apixaban / Rivaroxaban: Andexanet alfa or Prothrombin Complex Concentrate (4-Factor PCC / Octaplex / Beriplex ).

Warfarin: Vitamin K1 (Phytomenadione) IV/PO plus 4-Factor PCC for rapid reversal.